JPMorgan upgrades Sanofi stock rating to Overweight on favorable pipeline outlook

Published 08/08/2025, 08:06
JPMorgan upgrades Sanofi stock rating to Overweight on favorable pipeline outlook

Investing.com - JPMorgan has upgraded Sanofi (NASDAQ:SNY) (SAN:FP) from Neutral to Overweight while adjusting its price target to EUR105.00 from EUR110.00.

The upgrade comes after a first half of 2025 that included mixed pipeline readouts which had weighed on the pharmaceutical company’s shares, according to the investment bank.

JPMorgan sees a more favorable catalyst path for Sanofi’s upcoming readouts in the next 6-12 months, particularly for Amlitemab in Atopic Dermatitis and tolebrutinib in PPMS, with each trial likely to meet primary endpoints and deliver assets with over EUR1 billion in sales potential.

The firm notes that Sanofi is currently trading at 9x 2026 earnings and at a 20% discount to the sector despite projections of 5% sales CAGR and 7% EPS CAGR from 2025-2030, which is 50% above the sector average for EPS.

JPMorgan calculates Sanofi’s ex-pipeline Embedded Value at EUR105, suggesting the company is undervalued even if the pipeline assets were to be worth zero, making current price levels "a good entry point."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.